Development and validation of a predictive scoring system for in-hospital mortality in COVID-19 Egyptian patients: a retrospective study

• Published in: Scientific reports Vol. 12; no. 1; pp. 22352 - 11
• Main Authors: Elgohary, Mohamed AbdelSalam, Ali, Asmaa, El-Masry, Thanaa A., Faidah, Hani, Bantun, Farkad, Elkholy, Ahmad M., Fahim, Jaklin S., Elgamal, Nabila N., Mohamed, Mohamed Emam, Seadawy, Mohamed G., Helal, Amro M., De Waard, Michel, Shishtawy, Hesham M., El-Bouseary, Maisra M.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.12.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/326; 692/308; 692/499; 692/53; 692/700; Computed tomography; Coronaviruses; COVID-19; Egypt - epidemiology; Hospital Mortality; Humanities and Social Sciences; Humans; Leukocytes (neutrophilic); Lymphocytes; Middle Aged; Mortality; multidisciplinary; Patients; Pneumonia; Prognosis; Retrospective Studies; SARS-CoV-2; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Egypt
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-26471-w

SARS-CoV-2 virus has rapidly spread worldwide since December 2019, causing COVID-19 disease. In-hospital mortality is a common indicator for evaluating treatment outcomes. Therefore, the developing and validating a simple score system from observational data could assist in modulating the management procedures. A retrospective cohort study included all data records of patients with positive PCR for SARS-CoV-2. The factors that associated with mortality were analyzed, then allocation of potential predictors of mortality was executed using different logistic regression modeling, subsequently scoring system was developed from the most weighted predictors. The mortality rate of patients with COVID-19 pneumonia was 28.5% and 28.74%, respectively. The most significant factors that affected in-hospital mortality were old age (> 60 years), delay in hospital admission (> 4 days), high neutrophil/lymphocyte ratio “NLR” (> 3); higher computed tomography severity score; and CT-SS (> 20), in addition to using remdesivir and tocilizumab in the treatment protocol (P < 0.001 for all). The validity of the newly performed score was significant; the AUC was 85%, P < 0.001, and its prognostic utility was good; the AUC was 75%, P < 0.001. The prognostic utility of newly developed score system (EGY.Score) was excellent and could be used to adjust the treatment strategy of highly at-risk patients with COVID-19 pneumonia.